Table 5 Comparison of the long-term outcomes of the two groups.
Outcome | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
CLR (N = 106) | NOSES (N = 59) | p value | CLR (N = 59) | NOSES (N = 59) | p value | |
Status at the last follow-up (N%) | 0.32 | 0.29 | ||||
Survival | 77(72.6%) | 47(79.7%) | 42(71.2%) | 47(79.7%) | ||
Dead | 29(27.4%) | 12(20.3%) | 17(28.8%) | 12(20.3%) | ||
Local recurrence (N%) | 10(9.4%) | 4(6.8%) | 0.56 | 5(8.5%) | 4(6.8%) | 0.73 |
Distant metastasis (N%) | 11(10.4%) | 7(11.9%) | 0.77 | 7(11.9%) | 7(11.9%) | 1.00 |
Liver metastasis | 9(8.5%) | 5(8.5%) | / | 6(10.2%) | 5(8.5%) | / |
Lung metastasis | 2(1.9%) | 2(3.4%) | / | 1(1.7%) | 2(3.4%) | / |